FluoGuide A/S interview by BioStock Live now available
BioStock Lives interview with FluoGuide is now published. The presentation FluoGuide A/S (“FluoGuide” or “the Company”) did last week is available at BioStock Live and at FluoGuide’s respective webpages. The interview was made by Morten Albrechtsen, CEO, and Andreas Kjaer, CSO. FluoGuide is right now in the middle of the exercise period for the warrants of series TO 1 that was issued in connection with FluoGuide’s issue of units, prior to listing on Spotlight Stock Market. The exercise period runs until and including 7 May 2020. Upon full exercise of all warrants of series TO 1, FluoGuide will be allocated approximately DKK 6.4 million (before costs).
To watch the interview and presentation, please follow link. (https://fluoguide.com/investor/calendar-events/)
For more information regarding the exercise period of warrants – please follow link. (https://fluoguide.com/investor/filings-reports/)
For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
__________________________________________________________________________________
About FluoGuide
FluoGuide A/S (Spotlight Stock Market: FLUO:SS) provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide’s first product FG001 increases precision in cancer surgery by lighting up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to reduce suffering for the patients and increase the likelihood of cure. It can also reduce costs for the health care system for the benefit of society. FluoGuide focuses on demonstrating the effect of FG001 in patients by conducting a human proof-of-concept clinical trial and expects to announce the first result of this study during first half of 2020.
About FG001
FG001, FluoGuide’s first product, lights up the cancer and its invasive growth into the surrounding tissue. It helps the surgeon remove the entire tumor during surgery and increases the chance for complete cure of the patient. The task for the surgeon is simply to "turn the lights on and see the entire tumor". The solution helps surgeons remove a minimal amount of normal tissue while also reducing the risk of leaving cancer tissue behind. This reduces the suffering of the patient and increases the likelihood of cure, and also reduces costs for the health care system. FG001 is currently prepared for a proof-of-concept clinical study.
Tags: